The association of human milk oligosaccharides with glucose metabolism in overweight and obese pregnant women

• Published in: The American journal of clinical nutrition Vol. 110; no. 6; pp. 1335 - 1343
• Main Authors: Jantscher-Krenn, Evelyn, Treichler, Carmen, Brandl, Waltraud, Schönbacher, Lukas, Köfeler, Harald, van Poppel, Mireille NM
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2019; Oxford University Press; American Society for Clinical Nutrition, Inc
• Subjects: 3′siallylactose; Adult; Body weight; Breast milk; Diabetes mellitus; Fasting; Female; Gestation; Glucose; Glucose - metabolism; Humans; inflammation; Insulin; Longitudinal Studies; Metabolism; Milk; Milk, Human - chemistry; Milk, Human - metabolism; Obesity; Obesity - blood; Obesity - metabolism; Oligosaccharides; Oligosaccharides - blood; Oligosaccharides - metabolism; Overweight; Overweight - blood; Overweight - metabolism; Pregnancy; Pregnancy - blood; Pregnancy - metabolism; Prospective Studies; Regression analysis; Regression models; sialylation; Smoking; FUT; 3′SLN; LDFT; pregnancy; 3′SL; 2′FL; HMO; GDM; sialylation; 2AB; LNFP3; inflammation; GWG; 3′siallylactose; OGTT; obesity
• ISSN: 0002-9165; 1938-3207
• DOI: 10.1093/ajcn/nqz202

Human milk oligosaccharides (HMOs) were recently found in serum of normal-weight pregnant women, with concentrations increasing from early to mid- and late pregnancy. Whether HMOs have effects on maternal metabolism is unknown. We aimed to study the presence and changes in HMOs throughout pregnancy and assess associations with maternal glucose metabolism throughout pregnancy. The study was a prospective longitudinal cohort study including 87 overweight or obese women. Blood samples were taken at 15, 24, and 32 wk of pregnancy. In serum, 4 HMOs [2′-fucosyllactose (2′FL), lactodifucotetraose (LDFT), 3′-sialyllactose (3′SL), and 3′-sialyllactosamine (3′SLN)] were measured. In linear regression models, the associations between HMOs and (changes in) maternal metabolic parameters were assessed. All 4 HMOs showed a significant increase from 15 to 32 weeks of gestation. 3′SL and 3′SLN, but not 2′FL or LDFT, at 15 wk were positively associated with (changes in) fasting glucose at 24 and 32 wk. LDFT was positively associated with (changes in) insulin and HOMA-index at 24 but not 32 wk. A model to predict the development of gestational diabetes mellitus (GDM) that included fasting glucose, prepregnancy BMI, gestational weight gain, age, parity, smoking, and history of macrosomia resulted in an area under the curve (AUC) of 0.81 (95% CI: 0.70, 0.92). Adding 3′SL to this model increased the AUC to 0.91 (95% CI: 0.84, 0.97). The sialylated HMOs 3′SL and 3′SLN were associated with fasting glucose; LDFT was associated with fasting insulin and HOMA-index. Furthermore, 3′SL was more predictive of future GDM diagnoses than was fasting glucose in early pregnancy. Causal relations are unclear and need further investigation.